As per the agreement, Hovione and PSI will bring their spray-drying based sloid solution technologies to maximize the bioavailability of BCS Class II active pharmaceutical ingredients.
Development will be fast-tracked at both companies, with PSI developing the solubilization process and resulting drug product for their clients and Hovione managing the scale-up and industrialization of the spray drying process.
Hovione US Operations president Dave Hoffman said teaming up with PSI will give their customers an integrated solution which will allow them to go from drug product and process design to feasibility and development to industrial application in record time.